Display options
Cite
Sumiyoshi T, Kunugi H, Nakagome K. Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Front Neurosci. 2014;8:395doi: 10.3389/fnins.2014.00395.
Sumiyoshi, T., Kunugi, H., & Nakagome, K. (2014). Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Frontiers in neuroscience, 8395. https://doi.org/10.3389/fnins.2014.00395
Sumiyoshi, Tomiki, et al. "Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia." Frontiers in neuroscience vol. 8 (2014): 395. doi: https://doi.org/10.3389/fnins.2014.00395
Sumiyoshi T, Kunugi H, Nakagome K. Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Front Neurosci. 2014 Dec 04;8:395. doi: 10.3389/fnins.2014.00395. eCollection 2014. PMID: 25538549; PMCID: PMC4255483.
Copy Download .nbib Format: NLM
Share it on

Front Neurosci. 2014 Dec 04;8:395. doi: 10.3389/fnins.2014.00395. eCollection 2014.

Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia.

Frontiers in neuroscience

Tomiki Sumiyoshi, Hiroshi Kunugi, Kazuyuki Nakagome

Affiliations

  1. Department of Clinical Research Promotion, National Center Hospital, National Center of Neurology and Psychiatry Tokyo, Japan.
  2. Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry Tokyo, Japan.
  3. National Center Hospital, National Center of Neurology and Psychiatry Tokyo, Japan.

PMID: 25538549 PMCID: PMC4255483 DOI: 10.3389/fnins.2014.00395

Abstract

Negative symptoms (e.g., decreased spontaneity, social withdrawal, blunt affect) and disturbances of cognitive function (e.g., several types of memory, attention, processing speed, executive function, fluency) provide a major determinant of long-term outcome in patients with schizophrenia. Specifically, motivation deficits, a type of negative symptoms, have been attracting interest as (1) a moderator of cognitive performance in schizophrenia and related disorders, and (2) a modulating factor of cognitive enhancers/remediation. These considerations suggest the need to clarify neurobiological substrates regulating motivation. Genetic studies indicate a role for the monoamine systems in motivation and key cognitive domains. For example, polymorphism of genes encoding catecholamine-O-methyltransferase, an enzyme catabolizing dopamine (DA), affects performance on tests of working memory and executive function in a phenotype (schizophrenia vs. healthy controls)-dependent fashion. On the other hand, motivation to maximize rewards has been shown to be influenced by other genes encoding DA-related substrates, such as DARPP-32 and DA-D2 receptors. Serotonin (5-HT) receptors may also play a significant role in cognitive and motivational disabilities in psychoses and mood disorders. For example, mutant mice over-expressing D2 receptors in the striatum, an animal model of schizophrenia, exhibit both decreased willingness to work for reward and up-regulation of 5-HT2C receptors. Taken together, genetic predisposition related to 5-HT receptors may mediate the diversity of incentive motivation that is impaired in patients receiving biological and/or psychosocial treatments. Thus, research into genetic and neurobiological measures of motivation, in association with 5-HT receptors, is likely to facilitate intervention into patients seeking better social consequences.

Keywords: 5-HT receptors; cognition; dopamine; motivation; negative symptoms; psychosis; schizophrenia; serotonin

References

  1. Neuron. 2006 Feb 16;49(4):603-15 - PubMed
  2. Mol Psychiatry. 2004 Dec;9(12 ):1060-1 - PubMed
  3. Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22 - PubMed
  4. Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):20911-6 - PubMed
  5. Biol Psychiatry. 2011 May 15;69(10):928-35 - PubMed
  6. Schizophr Res. 2014 Sep;158(1-3):52-7 - PubMed
  7. J Neurosci. 2007 Jul 18;27(29):7731-9 - PubMed
  8. Schizophr Bull. 2011 Mar;37(2):334-43 - PubMed
  9. Schizophr Bull. 2014 Mar;40 Suppl 2:S107-16 - PubMed
  10. Am J Psychiatry. 2011 Nov;168(11):1195-201 - PubMed
  11. Neuropsychopharmacology. 2014 Apr;39(5):1125-34 - PubMed
  12. Front Behav Neurosci. 2013 Oct 16;7:140 - PubMed
  13. J Clin Psychopharmacol. 2014 Jun;34(3):396-7 - PubMed
  14. PLoS One. 2011;6(6):e20508 - PubMed
  15. Behav Neurosci. 2009 Aug;123(4):720-30 - PubMed
  16. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16311-6 - PubMed
  17. Science. 2007 Dec 7;318(5856):1642-5 - PubMed
  18. Biol Psychiatry. 2014 Nov 15;76(10):823-31 - PubMed
  19. Genes Brain Behav. 2013 Apr;12(3):311-22 - PubMed
  20. Am J Psychiatry. 2006 Oct;163(10):1826-9 - PubMed
  21. Curr Opin Pharmacol. 2011 Feb;11(1):59-67 - PubMed
  22. Schizophr Res. 2014 Jan;152(1):317-8 - PubMed
  23. Schizophr Res. 2014 Mar;153(1-3):209-13 - PubMed
  24. Nat Neurosci. 2009 Aug;12(8):1062-8 - PubMed

Publication Types